If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chr ...
If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a ...
Chronic back problems affect Black communities differently through factors like elevated prevalence rates of high-impact ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results